Lonza to Build Second Manufacturing Facility in Singapore

Lonza has broken ground for a new large-scale commercial mammalian cell-culture manufacturing facility in Singapore. This will be the second large-scale mammalian manufacturing plant in Singapore, and the third one globally, that the Swiss biopharmaceutical firm has built.

"In line with Lonza's strategy to develop its capabilities and expand the biopharmaceuticals business in the fast-growing Asian market, this facility marks an important milestone as Lonza reinforces its leading position as a global custom manufacturer of biopharmaceuticals," Stephan Kutzer, chairman of Lonza Biologics, said.

The facility, which will be completed at the latest in 2011, will have up to four mammalian bioreactor trains, each with a flexible capacity of up to 20,000 liters.

"I am very pleased that Lonza has decided to expand its biologics manufacturing base in Singapore," Singapore's Minister for Trade and Industry Lim Hng Kiang said. "This strategic partnership between Lonza and Bio*One has helped to build the biologics manufacturing capabilities and grow a critical mass of biologics activities in Singapore."